Drugs / AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00669136 | Jun 2009 → Mar 2013 | adult hepatocellular carcinoma | Lisa H. Butterfield, Ph.D. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00669136 ↗ |
| Known as | phAFP | “a plasmid expressing human AFP (phAFP)” NCT00669136 ↗ |
| Modality | Other / unclassified | “a plasmid expressing human AFP” NCT00669136 ↗ |
| Route | Intramuscular | “three intramuscular administrations of a plasmid expressing human AFP” NCT00669136 ↗ |